The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.
John C. Araujo
No relevant relationships to disclose
Geralyn C. Trudel
Employment or Leadership Position - Bristol-Myers Squibb; Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb; Bristol-Myers Squibb
Fred Saad
Consultant or Advisory Role - Bristol-Myers Squibb (U); Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Amgen; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Sanofi
Research Funding - Active Biotech/Ipsen; Active Biotech/Ipsen; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; ImClone Systems; ImClone Systems; Janssen Pharmaceutical ; Janssen Pharmaceuticals; Medivation; Medivation; Sanofi
Evan Y. Yu
Consultant or Advisory Role - Bristol-Myers Squibb (U); Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb
Joaquim Bellmunt
No relevant relationships to disclose
George Wilding
Consultant or Advisory Role - Bristol-Myers Squibb (U); Bristol-Myers Squibb (U)
John McCaffrey
No relevant relationships to disclose
Sergio V. Serrano
No relevant relationships to disclose
Vsevolod Matveev
No relevant relationships to disclose
Eleni Efstathiou
No relevant relationships to disclose
Stephane Oudard
Consultant or Advisory Role - Bayer; Bayer; Novartis; Novartis; Roche; Roche; Sanofi ; Sanofi
Honoraria - Bayer; Bayer; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche; Sanofi ; Sanofi
Michael J. Morris
Consultant or Advisory Role - Bayer (U); Bayer (U); Janssen Pharmaceutical (U); Janssen Pharmaceuticals (U); Millennium; Sanofi (U); Sanofi (U)
Research Funding - Agensys; Agensys; Algeta; Algeta; Bristol-Myers Squibb; Bristol-Myers Squibb; Genta; Genta; Johnson & Johnson; Medivation; Medivation; Sanofi
Bruce Sizer
Honoraria - Sanofi
Peter J. Goebell
Honoraria - Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer; Roche; Roche
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research; Institute of Cancer Research; Institute of Cancer Research
Prashni Paliwal
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Susan Durham
Employment or Leadership Position - Bristol-Myers Squibb; Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb; Bristol-Myers Squibb
Shinta Cheng
Employment or Leadership Position - Bristol-Myers Squibb; Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb; Bristol-Myers Squibb
Christopher Logothetis
No relevant relationships to disclose